Neurology Minute

In the first installment of this two-part series, Dr. Jeff Ratliff and Dr. Daniel Weintraub discuss the risks associated with the development of dementia in patients diagnosed with Parkinson disease. Show reference: https://www.neurology.org/doi/10.1212/WNL.0000000000209699  

In part two of this two-part series, Dr. Jeff Ratliff and Dr. Eduardo De Pablo-Fernández discuss why clinicians should be cautious when relying too much on dopaminergic imaging. Show reference: https://doi.org/10.1212/WNL.0000000000209453  

In part two of this two-part series, Dr. Tesha Monteith discusses the key features of long COVID.   Show reference: https://doi.org/10.17226/27768

In part one of this two-part series, Dr. Tesha Monteith discusses the 2024 National Academies of Sciences, Engineering, and Medicine formal definition of long COVID.  Show reference: https://doi.org/10.17226/27768

Dr. Jeff Ratliff and Dr. Eduardo De Pablo-Fernández discuss the strengths of dopamine transporter imaging or DAT imaging in diagnosing patients with Parkinsonian disorders. Show references: https://doi.org/10.1212/WNL.0000000000209453  

Dr. Dan Ackerman and Dr. Luciano A. Sposato discuss the topic of embolic stroke of undetermined sources and the controversies surrounding cardiac monitoring and anticoagulation. Show reference: https://www.neurology.org/doi/10.1212/WNL.0000000000209535  

Dr. Tesha Monteith provides an overview of the updated position statement on migraine prevention by the American Headache Society.  

In part two of this two-part series, Dr. Dan Ackerman and Dr. Gaspard Gerschenfeld discuss the differences in treatment between American Stroke Centers and those in France. Show reference: https://www.neurology.org/doi/10.1212/WNL.0000000000209398   

Dr. Meagan Seay discusses a relatively recently described but very interesting phenomenon called transient smartphone blindness. This is a phenomenon causing acute, painless, transient, monocular vision loss associated with smartphone use while lying down in the dark. Show reference: Transient Smartphone Blindness - EyeWiki  

Dr. Dan Ackerman and Dr. Gaspard Gerschenfeld discuss the efficacy and safety of both thrombolytics in patients with large ischemic core.  Show reference: https://www.neurology.org/doi/10.1212/WNL.0000000000209398   

Dr. Jason Crowell and Dr. Colin Hoy discuss the concept of prodromal Parkinson disease and the ethical considerations surrounding its diagnosis.  Show reference: https://www.neurology.org/doi/10.1212/WNL.0000000000209522  

In the last episode of this three-part series, Dr. Jeff Ratliff discusses how to approach patients presenting with emergent rigidity and difficulty moving.

In the second episode of this three-part series, Dr. Jeff Ratliff provides a rapid overview of hyperkinetic disorders that require urgent attention.

In the first episode of this three-part series, Dr. Jeff Ratliff discusses a few key points to help recognize and initiate treatment for patients with movement disorder emergencies, focusing on the initial approach to these disorders. It is important to consider medications, labs, and imaging as part of the evaluation process.

Dr. Halley Alexander and Dr. Kimford Meador discuss perinatal exposure to anti-seizure medications and its effects on creativity and executive function in children. Show reference: https://www.neurology.org/doi/10.1212/WNL.0000000000209448  

Dr. Matthew Barrett and Dr. Michael S. Okun discuss the caution and deliberation needed in understanding Parkinson disease biomarkers. Show reference: https://jamanetwork.com/journals/jamaneurology/article-abstract/2820441  

In the final episode of this two-part series, Dr. Joe Conway will discuss four biologic therapies that have been approved in recent years by the FDA for the treatment of adults with generalized myasthenia gravis. In this episode, he will talk about two of the treatment medications: Ravulizumab + zilucoplan. Show references: https://doi.org/10.1016/s1474-4422(21)00159-9 https://www.thelancet.com/jo...

In the final part of this two-part series, Dr. Andy Southerland and Dr. Lidia Moura discuss strategies on how clinicians can mitigate bias when using large language models. Show reference: https://www.neurology.org/doi/10.1212/WNL.0000000000209497  

Dr. Justin Abbatemarco, Dr. Michael R. Wilson, and Dr. John Pluvinage discuss their discovery of anti-CD320 antibodies in patients with neurologic manifestations of B12 deficiency and discuss the potential implications for diagnosis and treatment.  Show reference:  https://www.science.org/doi/10.1126/scitranslmed.adl3758  

In part one of the part-two series, Dr. Andy Southerland and Dr. Lidia Moura discuss the major findings related to large language models (LLMs) for neurologic care. Show reference: https://www.neurology.org/doi/10.1212/WNL.0000000000209497  

Dr. Justin Abbatemarco, Dr. Michael R. Wilson, and Dr. John Pluvinage introduce B12 deficiency and discuss challenges in measuring B12 levels in the serum. Show reference: https://www.science.org/doi/10.1126/scitranslmed.adl3758  

In the first episode of a two-part series, Dr. Joseph Conway will discuss four biologic therapies that have been approved in recent years by the FDA for the treatment of adults with generalized myasthenia gravis. In this episode, he will talk about two of the treatment medications: Efgartigimod and Rozanolixizumab. Show references: https://doi.org/10.1016/s1474-4422(21)00159-9 https://www.thelance...

Dr. Alison Christy delves into another women's history minute to discuss Marian Molly Putnam. 

Dr. Jason Crowell and Dr. Campbell Le Heron discuss tips and recommendations to help improve apathy in folks with Parkinson disease. Show references:  https://www.neurology.org/doi/10.1212/WNL.0000000000209301   

Dr. Jason Crowell and Dr. Campbell Le Heron discuss trying to assess for apathy in folks with Parkinson disease. Show references:  https://www.neurology.org/doi/10.1212/WNL.0000000000209301